Influence of Anaesthesia Type on Multiple Sclerosis Relapse
July 26, 2024 updated by: Varazdin General Hospital
Multiple Sclerosis Comparison of Relapse Incidence After General and Neuraxial Anesthesia: a Retrospective Observational Study
The influence of anesthesia on the course of multiple sclerosis is poorly investigated and the literature is limited.
The aim of this study is to investigate multiple sclerosis relapse after different types of anesthesia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The influence of anesthesia on the course of multiple sclerosis is poorly investigated and the literature is limited. A possible relapse after neuraxial anesthesia, it is believed to be associated with local anesthetic's toxicity and concentration.
The aim of this study is to investigate multiple sclerosis relapse after different types of anesthesia.
Study Type
Observational
Enrollment (Actual)
56
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This study included adult patientswith multiple sclerosis diagnosis who had undergone general or neuraxial anesthesia in General Hospital Varaždin during the period from 01.01.2012 to 31.12.2022.
Description
Inclusion Criteria:
- multiple sclerosis
- surgical procedure under general anaesthesia
- surgical procedure under neuraxial anaesthesia
Exclusion Criteria:
- patients (medical records) with incomplete data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
General anaesthesia
Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
|
Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
|
|
Neuraxial anaesthesia
Neuraxial anesthesia was administered using spinal or epidural injections of local anesthetic with or without opioid.
|
spinal or epidural injections of local anesthetic with or without opioid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multiple sclerosis relapse after 1 month
Time Frame: 1 month
|
Overall incidence of multiple sclerosis relapse after 1 month after anaesthesia
|
1 month
|
|
Multiple sclerosis relapse after 3 months
Time Frame: 3 months
|
Overall incidence of multiple sclerosis relapse after 3 months after anaesthesia
|
3 months
|
|
Multiple sclerosis relapse after 6 months
Time Frame: 6 months
|
Overall incidence of multiple sclerosis relapse after 6 months after anaesthesia
|
6 months
|
|
Multiple sclerosis relapse after 12 months
Time Frame: 12 months
|
Overall incidence of multiple sclerosis relapse after 12 months after anaesthesia
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Monika Kocman Panic, MD, Varazdin General Hospital, Varazdin, Croatia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2012
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
May 16, 2024
Study Registration Dates
First Submitted
July 23, 2024
First Submitted That Met QC Criteria
July 23, 2024
First Posted (Actual)
July 29, 2024
Study Record Updates
Last Update Posted (Actual)
July 30, 2024
Last Update Submitted That Met QC Criteria
July 26, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Multiple Sclerosis
- Sclerosis
- Recurrence
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics
Other Study ID Numbers
- 03072024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.